Viking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay Olson

แชร์
ฝัง
  • เผยแพร่เมื่อ 26 ก.พ. 2024
  • Jay Olson, Oppenheimer biotech analyst, joins 'Fast Money' to talk Viking's best trading day ever and the results of its obesity drug study.

ความคิดเห็น • 16

  • @TheGogobutt
    @TheGogobutt 3 หลายเดือนก่อน +5

    Very nice explanation of the little guys vs. the big guys. Will health insurance companies realize that perhaps paying for this drug in the short term saves them money in the long term? Maybe, maybe not.....jury is still out.

    • @556suppressor
      @556suppressor 3 หลายเดือนก่อน

      Hope this doesn't cost $1,000 per month. Insurance companies would rather pay for heart attack and stroke medical costs later on.

    • @DK-pj6le
      @DK-pj6le 2 หลายเดือนก่อน

      The market is huge. LLY will want to own the space and all the IP so they may buy VKTX. LLY and NVO are NOT overpriced. It's a $70 billion annual revenue market. Super disruptive drug - the medical community will be changed forever due to this new technology.

  • @umarabbasi7941
    @umarabbasi7941 3 หลายเดือนก่อน +6

    lol I bought five shares a year back because it was like 5$ and the name sounded cool. I should’ve bought more.

    • @vinay7397
      @vinay7397 3 หลายเดือนก่อน +2

      The next Viking could be Altimmune, they have good obesity data, they are at 12 dollars at the moment. They have good results and with more results their stock price will rise. Full disclosure, I have 60 shares of Viking which I bought 2 months ago, and 507 shares of Altimmune.

    • @kingkohli4952
      @kingkohli4952 หลายเดือนก่อน +1

      Is 68$ good price point for Viking? What do you predict the market price? Maybe in a year?

    • @umarabbasi7941
      @umarabbasi7941 หลายเดือนก่อน

      @@kingkohli4952 I honestly couldn’t tell you. lol I was just an idiot that got lucky.

    • @gabbs74
      @gabbs74 27 วันที่ผ่านมา

      @@kingkohli4952 shareholder here. I’m no analyst but from what I understand, seems like it has good support at 70, and with any relevant good news (M&A solid rumor, new developments on their trials, etc) it could easily go past previous high of 90 and maybe cross 100. I think it’s a good price to hold onto those shares. (no financial advice)

  • @martinmorris1197
    @martinmorris1197 3 หลายเดือนก่อน

    The real money is consumer one recession buy at discount.

  • @leswhynin913
    @leswhynin913 3 หลายเดือนก่อน +13

    The hottest drugs are fat loss 😂. We must be near the end of civilization

    • @4mb127
      @4mb127 3 หลายเดือนก่อน

      Obesity is the cause of many serious health conditions.

    • @kinglanky93
      @kinglanky93 3 หลายเดือนก่อน

      People been waiting on a fat loss drug for forever. My problem is that its created shortages for people who actually need medication for their diabetes.

  • @liudizzle
    @liudizzle 3 หลายเดือนก่อน +2

    How about this for a thought, put the fork down!

  • @HealthPoliticsAndProtein
    @HealthPoliticsAndProtein 3 หลายเดือนก่อน

    Yeah I’m sure all their data is absolutely honest, reliable, and expensive. Give me a break.